Epidemiological Services
Solve your European oncology challenges with evidence-based analysis and representative data.
Confident decision-making with data you can trust
Unlock stronger decision-making, targeting, sampling, and understanding of health outcomes with our evidence-based analysis and representative data.
Backed by our strong record of successful HTA submissions, depth of experience, and partnerships with physicians and healthcare providers, you can be confident you’re in good hands.
Rigorous, representative, and regulation-ready
Every TriNetX dataset is representative, regulation-standard, and customizable to your specific study needs, so you can make confident, evidence-based decisions across regions and therapeutic areas.
Global expertise, whenever you need it
From study design to regulatory submission, our team of leading analysts, strategists, and epidemiologists is on hand to provide support and guidance whenever you need them.
With deep oncology and epidemiology experience, we ensure your research is rigorous, your submissions are airtight, and your data is tailored to achieve your specific research goals.
How we support you
Tailored research methodology.
Our research methodologies account for regional service provider distribution, population density, and healthcare infrastructure.
This ensures representative study populations and adaptability across therapeutic areas and geographies, enabling data-driven decisions for resource allocation and treatment pattern analysis across diverse indications.
Mapping key institutions
- We begin with a detailed analysis of the care structure to identify relevant institutions.
- We utilize hospital quality reports, professional directories, and other data sources to map out treatment facilities.
- We define relevant centers through ABC analysis and case-volume assessments to form a robust foundation for further research.
Identification of key treatment centers
- We target both public and private healthcare sectors, including university hospitals, regional clinics, and private practice specialists.
- This comprehensive mapping ensures coverage across the entire care continuum, creating a representative, valid population for further studies.
Targeted data collection
- We collect primary aggregated epidemiological data (e.g. screener surveys) to gather specific patient numbers for targeted conditions.
- We ensure proportional sampling across facility types while mitigating biases (e.g. regional or institutional focus).
- We collect retrospective and real-time data from patient records to support incidence and prevalence extrapolation.
Want to learn more?
Explore our insights
Run time: 8 mins. As global privacy regulations tighten, researchers can no longer rely on centralizing patient data to conduct multi-site studies — yet the demand for large-scale real-world evidence has never been higher.
The way smoking data get lost illustrates exactly how structured clinical datasets systematically fail to capture what’s clinically meaningful, and why that matters for every AI model built on them.
The milestone reflects accelerating international growth and gives pharmaceutical companies, academic researchers, healthcare providers, and health-tech innovators access to trusted, current, clinically rich, and globally representative real-world data.
The clinical trial industry has made a significant bet on artificial intelligence. The investment has been substantial. The results have been harder to quantify.
Contact TriNetX
Need to reach out? We’re here to help.
"*" indicates required fields
